title: For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
authors.affiliation: Department of Psychiatry, University of Melbourne, Australia. ipaj-ed@unimelb.edu.au
authors.forename: David
authors.initials: D
authors.lastname: Ames
authors.forename: Hanna
authors.initials: H
authors.lastname: Kaduszkiewicz
authors.forename: Hendrik
authors.initials: H
authors.lastname: van den Bussche
authors.forename: Thomas
authors.initials: T
authors.lastname: Zimmermann
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Birks
authors.forename: Deborah
authors.initials: D
authors.lastname: Ashby
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D000077265:Donepezil; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010880:Piperidines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil